The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
April 12th 2024
Patients with radiographic axial spondyloarthritis (ax-SpA) and a high risk of radiographic progression had similar low progression on both secukinumab and an adalimumab biosimilar.
December 31st 2023
What's in a Name — FDA Urged Not to Give Biosimilars Unique Names
July 7th 2014This week, a coalition of 32 major pharmacies, health insurers, unions and pension plans asked the FDA not to require distinct names for biosimilar medications, arguing that such a move would not compromise patient safety, but could undermine the savings that are expected to be generated as these medicines are introduced into the US health care system.
Read More
UnitedHealthcare Bars Copay Coupons for Specialty Drugs
November 5th 2012According to a report by Elsevier's BusinessIntelligence, UnitedHealthcare has announced that pharmacies that are participating in its Designated Specialty Pharmacy network will no longer redeem manufacturer-sponsored coupons as an offset to member cost-sharing payments for 6 specialty drugs beginning January 1, 2013.
Read More
Industry Voices: Biosimilars and Trade Secrets
October 31st 2012Trade secrets may potentially be used to protect manufacturing processes for biological drugs--yet there is concern that the new law on biosimilars, the BPCIA (Biologics Price Competition and Innovation Act of 2009), and the accompanying FDA regulations, may expose trade secrets of both originators and biosimilar applicants.
Read More
The Challenges in Manufacturing Biologics [Video]
August 22nd 2012This content is brought to you by Amgen This video summarizes the complex process of creating biologics from start to finish and describes some of the unique challenges-- and tremendous effort-- involved in delivering safe and effective biologics.
Read More
Study Documents How Price of TNF Inhibitors Rose After New Competition
January 1st 2003A study of cost trends for tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis (RA) after the entry of new competition showed that the newer drugs did not lower costs, and in fact, the annual treatment costs of the existing medicines rose by $17,390. Taxpayer funds shouldered all of the increases, and the “findings illustrate a market failure contributing to the rising costs of prescription drugs,” according to the researchers.
Read More
Study Documents How Price of TNF Inhibitors Rose After New Competition
January 1st 2003A study of cost trends for tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis (RA) after the entry of new competition showed that the newer drugs did not lower costs, and in fact, the annual treatment costs of the existing medicines rose by $17,390. Taxpayer funds shouldered all of the increases, and the “findings illustrate a market failure contributing to the rising costs of prescription drugs,” according to the researchers.
Read More
Advisory Council Supports Biosimilars in Call for Universal Public Drug Coverage in Canada
January 1st 2000A Canadian advisory council is recommending the use of biosimilars in a final report that lays out 60 recommendations for how the country can create a $15.3 billion (approximately US $11,408,521,500) universal, single-payer, public system for pharmaceutical coverage.
Read More
Celltrion Presents More Data Showing Comparable Efficacy, Safety of Subcutaneous CT-P13 to IV Form
January 1st 2000Korean drug maker Celltrion Healthcare recently presented new findings from a 2-part study at the Annual European Congress of Rheumatology 2019 meeting about subcutaneous biosimilar CT-P13 (Inflectra, Remsima).
Read More
ACR Supports Continued Use of Telemedicine and Reimbursement Parity After COVID-19 Crisis
December 1st 1997The widespread adoption of telemedicine during the coronavirus disease 2019 (COVID-19) pandemic, as well as reimbursement parity that was enacted by CMS, should be continued once the public health emergency passes, according to a new position statement by the American College of Rheumatology (ACR).
Read More